Background: Asthma medication reduction is common in early pregnancy and may be an important contributor to worsening asthma in pregnancy.
Methods: In a prospective cohort study, self-reported current and past asthma medications were collected and analyses compared measures of asthma status in women who discontinued asthma medication in the six months prior to enrollment (“step down”) versus those who did not (“no change”). Evaluation of asthma was done at three study visits (one per trimester) and by daily diaries, including measures of lung function (percent predicted forced expiratory volume in one and six seconds, (%FEV1, %FEV6), peak expiratory flow (%PEF), forced vital capacity (%FVC), FEV1 to FVC ratio (FEV1/FVC)), lung inflammation (fractional exhaled nitric oxide (FeNO), ppb), rate of asthma symptoms (activity limitation, night symptoms, rescue inhaler use, wheeze, shortness of breath, cough, chest tightness, chest pain), and rate of asthma exacerbations. Adverse pregnancy outcomes were also evaluated. Adjusted regression analyses examined whether adverse outcomes differed by periconceptional asthma medication changes.
Results: Of 279 participants included in analyses, 135 (48.4%) did not change asthma medication in the periconceptional period while 144 (51.6%) reported a step down in medication. Those in the step-down group were more likely to have milder disease (88 (61.1%) in the step-down versus 74 (54.8%) in the no change group), exhibited less activity limitation (rate ratio (RR): 0.68, 95% CI 0.47–0.98), and experienced fewer asthma attacks (RR: 0.53, 95% CI 0.34–0.84) during pregnancy. Women in the step-down group had a non-significant increase in overall odds of experiencing an adverse pregnancy outcome (odds ratio 1.62, 95% CI 0.97–2.72).
Conclusions: Over half of women with asthma reduce asthma medication in the periconceptional period. Although these women typically have milder disease, a step down in medication may be associated with an increased risk of adverse pregnancy outcomes.